Search

Your search keyword '"Agathe Tostivint"' showing total 4 results
Start Over Author "Agathe Tostivint"
4 results on '"Agathe Tostivint"'

1. Cost-utility analysis of transcranial direct current stimulation (tDCS) in non-treatment-resistant depression: the DISCO randomised controlled study protocol

Author

Christelle Volteau, Pierre-Michel Llorca, Valéry-Pierre Riche, Anne Sauvaget, Lydie Lagalice, Solène Schirr-Bonnans, Morgane Péré, Cécile Dert, Annabelle Rivalland, Fabienne Tessier, Adeline Lepage, Agathe Tostivint, Thibault Deschamps, Véronique Thomas-Ollivier, Alison Robin, Noémie Pineau, Clémence Cabelguen, Nicolas Bukowski, Marie Guitteny, Auxane Beslot, Luc Simons, HUGOPSY Network, Jean-Marie Vanelle, Giordano D'Urso, Samuel Bulteau, Bénédicte Gohier, Marine Rozet, Djamila Bennabi, Emmanuel Haffen, Christophe Daudet, Ludovic Samalin, Benoît Trojak, Jean-Christophe Chauvet-Gélinier, Emmanuel Poulet, Charline Magnin, Stéphane Mouchabac, Ghina Harika Germaneau, Nemat Jaafari, Dominique Drapier, Jean-Marie Batail, Maud Rotharmel, Caroline Berjamin, Wissam El Hage, and Thomas Desmidt

Subjects
Medicine
Abstract

Introduction Depression is among the most widespread psychiatric disorders in France. Psychiatric disorders are associated with considerable social costs, amounting to €22.6 billion for treatment and psychotropic medication in 2011. Treatment as usual (TAU), mainly consisting of pharmacotherapy and psychotherapy, is effective for only a third of patients and in most cases fails to prevent treatment resistance and chronicity. Transcranial direct current stimulation (tDCS) consists in a non-invasive and painless application of low-intensity electric current to the cerebral cortex through the scalp. Having proved effective in depressed patients, it could be used in combination with TAU to great advantage. The objective is to compare, for the first time ever, the cost-utility of tDCS-TAU and of TAU alone for the treatment of a depressive episode that has been refractory to one or two drug treatments.Methods and analysis This paper, based on the DISCO study protocol, focuses on the design of a prospective, randomised, controlled, open-label multicentre economic study to be conducted in France. It will include 214 patients with unipolar or bipolar depression, assigning them to two parallel arms: group A (tDCS-TAU) and group B (TAU alone). The primary outcome is the incremental cost-effectiveness ratio, that is, the ratio of the difference in cost between each strategy to the difference in their effects. Their effects will be expressed as numbers of quality-adjusted life-years, determined through administration of the EuroQol Five-Dimension questionnaire over a 12-month period to patients (EQ-5D-5L). Expected benefits are the reduction of treatment resistance and suicidal ideation as well as social and professional costs of depression. Should depression-related costs fall significantly, tDCS might be considered an efficient treatment for depression.Ethics and dissemination This protocol has been approved by a French ethics committee, the CPP-–Est IV (Comité de Protection des Personnes–Strasbourg). Data are to be published in peer-reviewed medical journals.Trial registration number RCB 2018-A00474-51; NCT03758105

Published
2020
Full Text
View/download PDF

2. Cost-utility analysis of transcranial direct current stimulation (tDCS) in non-treatment-resistant depression: the DISCO randomised controlled study protocol

Author

Morgane Péré, Clémence Cabelguen, Luc Simons, Giordano D’Urso, Cécile Dert, Noémie Pineau, Thibault Deschamps, Réseau Hugopsy, Solène Schirr-Bonnans, Annabelle Rivalland, Samuel Bulteau, Valery-Pierre Riche, Nicolas Bukowski, Auxane Beslot, Lydie Lagalice, Jean-Marie Vanelle, Christelle Volteau, Marie Guitteny, Fabienne Tessier, Alison Robin, Adeline Lepage, Agathe Tostivint, Anne Sauvaget, Véronique Thomas-Ollivier, Motricité, interactions, performance EA 4334 / Movement - Interactions - Performance (MIP), Le Mans Université (UM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR des Sciences et Techniques des Activités Physiques et Sportives (UFR STAPS), Université de Nantes (UN)-Université de Nantes (UN), Centre hospitalier universitaire de Nantes (CHU Nantes), Comportement et noyaux gris centraux = Behavior and Basal Ganglia [Rennes], Université de Rennes (UR)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes = Institute of Clinical Neurosciences of Rennes (INCR), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, project PRME-17-0097, French Ministry of Health, CHU Pontchaillou [Rennes]-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université européenne de Bretagne - European University of Brittany (UEB)-Institut des Neurosciences Cliniques de Rennes (INCR), Motricité, interaction, performance EA 4334 (MIP), Le Mans Université (UM)-Université de Nantes - UFR des Sciences et Techniques des Activités Physiques et Sportives (UFR STAPS), Institut des Neurosciences Cliniques de Rennes (INCR)-CHU Pontchaillou [Rennes]-Université européenne de Bretagne - European University of Brittany (UEB)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes (INCR)

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Cost-Benefit Analysis, [SDV]Life Sciences [q-bio], Transcranial Direct Current Stimulation, tDCS, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Health Economics, Quality of life, Medicine, Humans, Prospective Studies, cost-utility, Suicidal ideation, Depression (differential diagnoses), ComputingMilieux_MISCELLANEOUS, Protocol (science), Cost–utility analysis, Transcranial direct-current stimulation, treatment, business.industry, Depression, General Medicine, medicine.disease, 3. Good health, 030227 psychiatry, England, quality of life, depression & mood disorders, Physical therapy, Female, Quality-Adjusted Life Years, medicine.symptom, business, Treatment-resistant depression, 030217 neurology & neurosurgery, Follow-Up Studies, study protocol
Abstract

IntroductionDepression is among the most widespread psychiatric disorders in France. Psychiatric disorders are associated with considerable social costs, amounting to €22.6 billion for treatment and psychotropic medication in 2011. Treatment as usual (TAU), mainly consisting of pharmacotherapy and psychotherapy, is effective for only a third of patients and in most cases fails to prevent treatment resistance and chronicity. Transcranial direct current stimulation (tDCS) consists in a non-invasive and painless application of low-intensity electric current to the cerebral cortex through the scalp. Having proved effective in depressed patients, it could be used in combination with TAU to great advantage. The objective is to compare, for the first time ever, the cost-utility of tDCS-TAU and of TAU alone for the treatment of a depressive episode that has been refractory to one or two drug treatments.Methods and analysisThis paper, based on the DISCO study protocol, focuses on the design of a prospective, randomised, controlled, open-label multicentre economic study to be conducted in France. It will include 214 patients with unipolar or bipolar depression, assigning them to two parallel arms: group A (tDCS-TAU) and group B (TAU alone). The primary outcome is the incremental cost-effectiveness ratio, that is, the ratio of the difference in cost between each strategy to the difference in their effects. Their effects will be expressed as numbers of quality-adjusted life-years, determined through administration of the EuroQol Five-Dimension questionnaire over a 12-month period to patients (EQ-5D-5L). Expected benefits are the reduction of treatment resistance and suicidal ideation as well as social and professional costs of depression. Should depression-related costs fall significantly, tDCS might be considered an efficient treatment for depression.Ethics and disseminationThis protocol has been approved by a French ethics committee, the CPP-–Est IV (Comité de Protection des Personnes–Strasbourg). Data are to be published in peer-reviewed medical journals.Trial registration numberRCB 2018-A00474-51;NCT03758105

Published
2020
Full Text
View/download PDF

3. Hospital production cost of transcranial direct current stimulation (tDCS) in the treatment of depression

Author

Solène Schirr-Bonnais, Nicolas Mauduit, Olivier Sellal, Cécile Dert, François Etcheverrigaray, Anne Pichot, Anne Sauvaget, Samuel Bulteau, Christophe Leux, Agathe Tostivint, Johann Clouet, Valéry-Pierre Riche, Clémence Cabelguen, Département d'addictologie et de psychiatrie de liaison [CHU de Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Motricité, interaction, performance EA 4334 (MIP), Le Mans Université (UM)-Université de Nantes - UFR des Sciences et Techniques des Activités Physiques et Sportives (UFR STAPS), Université de Nantes (UN)-Université de Nantes (UN), Pharmacie [CHD Vendée], Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon, Département Partenariat et Innovation [CHU Nantes] (Cellule d'innovation), Centre hospitalier universitaire de Nantes (CHU Nantes)-Direction des Affaires Médicales et de la Recherche [CHU Nantes] (DAMR), Regenerative Medicine and Skeleton research lab (RMeS), Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), UFR d’Odontologie [CHU Hôtel Dieu, Nantes], Université de Nantes (UN), Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, PHU 11 Pharmacie [CHU Nantes] (Pharmacie Centrale), Département de l'Information Médicale [CHU Nantes], MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, This work has been supported by a grant from the FrenchHealth Ministry for the DISCO study PRME-2017-0097., Motricité, interactions, performance EA 4334 / Movement - Interactions - Performance (MIP), Université de Nantes - UFR des Sciences et Techniques des Activités Physiques et Sportives (UFR STAPS), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Le Mans Université (UM), Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Nantes - UFR Odontologie, Jehan, Frederic, Le Mans Université (UM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR des Sciences et Techniques des Activités Physiques et Sportives (UFR STAPS), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Regenerative Medicine and Skeleton (RMeS), École nationale vétérinaire, agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques

Subjects
Cost, medicine.medical_treatment, Cost accounting, Transcranial Direct Current Stimulation, 050105 experimental psychology, TDCS, 03 medical and health sciences, 0302 clinical medicine, Health Economics, Multidisciplinary approach, Physiology (medical), Medicine, Humans, 0501 psychology and cognitive sciences, Operations management, Economics, Hospital, Neurostimulation, Health policy, Depression (differential diagnoses), health care economics and organizations, Psychiatry, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Health economics, [SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, Transcranial direct-current stimulation, business.industry, Depression, Health Policy, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, 05 social sciences, Usability, General Medicine, Hospitals, 3. Good health, Treatment Outcome, Neurology, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Neurology (clinical), France, business, 030217 neurology & neurosurgery
Abstract

Summary Objectives Due to its ease of use, tolerance, and cost of acquisition, transcranial direct current stimulation (tDCS) could constitute a credible therapeutic option for non-resistant depression in primary care, when combined with drug management. This indication has yet to receive official recognition in France. The objective of this study is to evaluate the production cost of tDCS for the treatment of depression in hospitals, under realistic conditions. Methods The methodology adopted is based on cost accounting and was validated by a multidisciplinary working group. It includes equipment, staff, and structural costs to obtain the most realistic estimate possible. We first estimated the cost of producing a tDCS session, based on our annual activity objective, and then estimated the cost of a 15-session treatment program. This was followed up with a sensitivity analysis applying appropriate parameters. Results The hospital production cost of a tDCS depression treatment program for a single patient was estimated at €1555.60 euros: €99 in equipment costs, €1076.95 in staff costs, and €379.65 in structural costs. Conclusion This cost analysis should make it possible to draw up pricing proposals in compliance with regulations and health policy choices and to develop health-economic studies. This would ultimately lead to official recognition of tDCS treatment for depression in France and pave the way for studying various scenarios of coverage by the French national health insurance system.

Published
2018
Full Text
View/download PDF

4. Hospital production cost of direct transcranial stimulation (tDCS) in the treatment of depression

Author

Cécile Dert, Samuel Bulteau, Nicolas Mauduit, Clémence Cabelguen, Anne Pichot, Agathe Tostivint, François Etcheverrigaray, Olivier Sellal, S. Schirr-Bonnais, Johann Clouet, Anne Sauvaget, Valery-Pierre Riche, and Christophe Leux

Subjects
medicine.medical_specialty, Transcranial direct-current stimulation, business.industry, medicine.medical_treatment, Public health, Cost accounting, Usability, Psychiatry and Mental health, Electroconvulsive therapy, Arts and Humanities (miscellaneous), Multidisciplinary approach, Physical therapy, medicine, Production (economics), business, health care economics and organizations, Health policy
Abstract

Introduction Transcranial Direct Current Stimulation (tDCS), a medical device, has Grade B evidence-based efficacy for treatment-naive depressive patients, or with treatment, and no resistance. Its ease of use, its good tolerance and its cost of acquisition, lower than transcranial magnetic stimulation and electroconvulsive therapy, make it a good candidate as a therapeutic alternative in non-resistant depressions in primary care, associated with a medication management. No pricing or economic valuation currently exists for the tDCS in psychiatry. To our knowledge, no medical-economic evaluation has been conducted on tDCS. The objective of this study is to evaluate the cost of producing tDCS in the treatment of depression in hospitals, in real and pragmatic conditions. Methodology The methodology, derived from cost accounting, was validated by a multidisciplinary working group (clinicians, public health doctors, pharmacists, administrative, financial and health economists). Pragmatic, based on official and institutional documentary sources and field practice, she integrated the costs of materials, personnel and structure, to have an estimate closer to reality. We first estimated the cost of producing a tDCS session, based on our annual activity goal, and then the cost of a 15-session course. Sensitivity analysis, based on relevant parameters, supplemented these estimates. Results The cost of hospital production of a tDCS treatment in the treatment of depression was estimated at 1555.6 euros (99 € of material, 1 076.95 € of staff, 379.65 € of structural charges). Conclusion This cost analysis should be able to serve as a basis for other replication work, in other conditions (outpatient centers, specialized institutions, clinics), to arrive at a more general average estimate, with cost variability studies. And allow the development of pricing proposals, in compliance with regulations and health policy choices, and the development of medico-economic studies.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results